Renal graft

Kuypers, D.R.J. 2005. Immunosuppressive drug monitoring What to use in clinical practice today to improve renal graft outcome. Transplant Int. 18 140. 

Bertolone G, Andriani M, Bonucci E, et al. 1993. Dynamics of bone aluminum over one year of functioning renal graft. Nephron 64 540-546. 

Ekberg H, Swensson PJ, Simanaitis M, et al, Factor V R506Q mutation (activated protein C resistance) is additional risk factor for early renal graft loss associated with acute vascular rejection, Transplantation 2000 69(8) I 577-1 581. 

Calcium channel blockers are given to transplant patients for their protective effect against cidosporin-induced nephrotoxicity and to optimize ciclosporin immunosuppression in order to reduce early rejection of renal grafts. Nifedipine has been used to treat cidosporin-induced hypertension, although amlodipine may be just as effective (185). 

Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y Lacidipine Study Group. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients a prospective randomized placebo-controlled 2-year study. Transplantation 2004 78(8) 1204-11. 

Recombinant human erythropoietin (epoetin and darbepoetin) provides effective therapy with a very favorable risk-benefit ratio in hemodialysis patients with end-stage chronic renal insufficiency, and in patients with progressive renal insufficiency who are not yet being dialysed (1). It improves cognitive function and the quality of life of patients with chronic uremia (2-5) and is very effective in children with chronic renal graft rejection and anemia (6). It also offers new opportunities for treating anemia in non-uremic patients. In patients with chemotherapy-induced anemia, epoetin increases hemoglobin concentration, reduces transfusion requirements, and improves quality of life (7,8). The response rate to epoetin in patients with multiple myeloma and anemia, which is 55-85% (9), increases when GM-CSF or G-CSF is... 

Possible deleterious effects of interferon alfa on renal graft function are repeatedly reported (280). 

Bren A, Kandus A, Ferluga D. Rapidly progressive renal graft failure associated with interferon-alpha treatment in a patient with chronic myelogenous leukemia. Clin Nephrol 1998 50(4) 266-7. 

Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992 339 (8796) 777-8. 

Hollenbeck M, Westhoff A, Bach D, Grabensee B, Kolvenbach R, Kniemeyer HW. Doppler sonography and renal graft vessel thromboses after OKT3 treatment. Lancet 1992 340(8819) 619-20. 

Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991 66(4) 343-7. 

Hurault de Ligny B, El Haggan W, Comoz F, et al. Early loss oftwo renal grafts obtained from the same donor role of ecstasy Transplantation. 2005 80(1 ) 153-156. 

Renal transplant pahents with hepatitis C seem to be especially susceptible to injury from IFNa. IFNa triggers renal graft rejection in a substantial number of patients, and is now considered contra-indicated in this setting [58, 59]. 

Despite cessation of the exposure to Chinese herbs, progression of renal failure is usually relentless over a period of few months to several years. Six year after the withdrawal of the incriminated herbs from the Belgian market, more than 100 patients with CHN were confirmed in Belgium, 30 % of them having a moderate renal failure and 70 % being treated by maintenance dialysis or renal grafting [6]. 

Francois H, Durrbach A, Amor M, Djeffal R, Kriaa F, Paradis V, et al. The long-term effect of switching from cyclosporin A to mycophenolate mofetil m chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 2003 18 1909-16. 

Kotanko R Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid (letter). Nephron 2002 90 234-235. 

W23. Williams, D., Wickramasinghe, S. N., and Hulme, B., Effects ofazathioprine therapy on the MCV of patients with renal grafts. Scand. ]. Haematol. 20, 258-264 (1978). 

Abrahamson DR, St. John PL, Pillion DL, Tucker DC. Glomerular development in intraocular and intra renal grafts of fetal kidneys. Lab. Invest. 1991 64 629-639. 

Delayed recovery of post-transplant renal allograft dysfunction was seen more often in the past when elevated doses of cyclosporine were used, principally with the concomitant occurrence of prolonged ischemic times. This event has been largely diminished by the delay of onset of CsA administration until good renal graft function is present or by the use of alternative schedules for induction of immunosuppression that spare calcineurin blockers [2, 3]. Withdrawal of CsA in renal transplant patients with delayed graft function has been associated with less severe and shorter renal dysfunction [274]. 

Savary E, Nemes B, Jaray J, Dinya E, Borka P, Varga M, Sulyok B, Remport A, Toth A, Perner F. Prediction of early renal graft function by the measurement of donor urinary glutathione S-transferase. Transplantation 2000 69 1398-1402. 

Stockenhuber, F., Steininger, R., Apperl, A., Muehlbacher, F., Patek, E., Sautner, T., Sertl, K., Graninger, W., Hauser, A. C., and Baicke, P. Soluble interleukin-2 receptor A novel parameter of renal graft rejection. Transplant. Proc. 22, 165-166 (1990). 

---